News

In the News

  • 07.29.2022  |  CARB-X: Accelerating Global Antibacterial Innovation to Combat Resistance

    The MTPConnect Podcast | On a visit to Australia, CARB-X Chief Scientific Officer Dr Richard Alm (originally from Adelaide) joins the podcast to discuss the threat of antimicrobial resistance, the need to take a ‘village approach’ to develop new life-saving antimicrobial treatments, why it’s time for an AMR accelerator in Australia and tips for Australian start-ups & researchers on applying for future CARB-X funding rounds!

    Full Story

  • 07.15.2022  |  Antibiotic-resistant infections could dwarf COVID-19 pandemic

    Boston Globe | These life-saving drugs are being taken for granted and many bacteria have become resistant to them.

    Full Story

  • 07.15.2022  |  As Big Pharma Loses Interest in New Antibiotics, Infections Are Only Growing Stronger

    Kaiser Health | Forget covid-19, monkeypox, and other viruses for the moment and consider another threat troubling infectious disease specialists: common urinary tract infections, or UTIs, that lead to emergency room visits and even hospitalizations because of the failure of oral antibiotics.

    Full Story

  • 07.14.2022  |  Major Layoffs Underscore Continuing Struggle to Develop New Antibiotics

    PEW | Economic incentives could help sustain efforts to bring new and effective drugs to market

    Full Story

  • 07.14.2022  |  How the pandemic screwed up our antibiotics

    Vox | Antibiotic resistance was already a crisis. Covid-19 made it an emergency.

    Full Story

  • 07.12.2022  |  WHO Issues Urgent Call to Develop New Vaccines to Tackle Drug-Resistant Bacteria

    Health Policy Watch | With antimicrobial resistance (AMR) on the rise globally, the World Health Organization (WHO) Tuesday issued an urgent call to step up investment and research into vaccine candidates that can tackle the problem of drug-resistant bacteria in a new report that looks at key research gaps and opportunities.

    Full Story

  • 06.30.2022  |  Addressing Antimicrobial Resistance

    ASPR BLOG | Dawn O’Co​nnell, HHS Assistant Secretary for Preparedness and Response, discusses the next phase of the partnership with CARB-X to address antimicrobial resistance. “There is no single solution to address the threat of antimicrobial resistance, but our global partnership to build an innovative, diverse array of pre-clinical and early clinical products is making meaningful progress. I look forward to seeing the investments that we make today in time, funding, and expertise translate into a portfolio of tools that save lives in future disasters.​”

    Full Story

  • 06.23.2022  |  SpeeDx RNA/DNA Ratio Method Shows Promise for Bacterial Viability, Susceptibility Testing

    GENOMEWEB | SpeeDx has created a phenotypic test, based on the RNA/DNA ratio of a diagnostic target gene, to determine viability and antimicrobial susceptibility of bacteria. SpeeDx intends to debut the technology, branded InSignia™, as part of a lab-based gonorrhea susceptibility test and ultimately to incorporate it into a CARB-X-funded point-of-care testing platform that it is codeveloping with QuantumDx.

    Full Story

  • 06.15.2022  |  UK to Roll Out Drugs From Pfizer, Shionogi to Fight Superbugs

    Bloomberg | England is rolling out a pair of antibiotics from Pfizer Inc. and Shionogi & Co. as part of a pioneering program aimed at stimulating a broken market and taking on the rising threat of superbugs.

    Full Story

  • 06.13.2022  |  Fighting Superbugs: How an Indian Avenger is building a life-saving weapon

    FORBES INDIA | Big pharma has little interest in antibiotics because there’s not enough money in it, making Bugworks, with its R&D in India, among a handful of startups that is attempting the impossible.

    Full Story

  • 06.10.2022  |  HHS Promises up to $300 Million Over 10 Years to Fight Antibiotic-Resistant Bacteria

    Healtcare Weekly | The U.S. Department of Health and Human Services (HHS) announced it will commit $20 million this year and can provide up to $300 million over the next 10 years to fight antimicrobial resistant (AMR) infections through the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).

    Full Story

  • 06.01.2022  |  Boosting innovation in antibacterials: Pitfalls and potential solutions

    BioPharma Reporter | A well-funded and appropriately rewarded biotech ecosystem is needed for the next generation of antibacterials to reach the clinic and beyond, according to BIO’s State of Innovation in Antibacterial Therapeutics report

    Full Story

  • 05.26.2022  |  Inside Locus Biosciences’ $35M funding: What it means for gene editing startup in RTP

    WRAL |Gene editing startup Locus Biosciences is another step closer to actualizing its biotherapeutics against bacterial diseases after landing $35 million in additional capital.

    Full Story

  • 05.25.2022  |  Antibiotic Resistance Could Be a Top Cause of Death by 2050, Experts Say – Can targeted investments rebuild the antibiotic pipeline?

    MEDPAGE TODAY | A global coalition is necessary to ensure countries around the world benefit from the antibiotics that result from current innovations.

    Full Story

  • 05.24.2022  |  HHS to invest up to $300M over next 10 years into CARB-X efforts to combat antimicrobial resistant infections

    HOMELAND PREPAREDNESS NEWS | Beginning with $20 million this year, the United States Department of Health and Human Services (HHS) will commit up to $300 million to support antimicrobial resistant (AMR) infection research conducted through the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) over the next decade.

    Full Story

  • 05.23.2022  |  A Better Way to Fund the Fight Against Superbugs

    BLOOMBERG | As bacteria become increasingly resistant to antibiotics, the pipeline of drugs to counter so-called superbugs has virtually dried up. Three years after announcing a strategy to boost investment in antibiotics, England is poised to fund a pair of new drugs by offering companies a fixed annual fee regardless of how much—or how little—they’re used.

    Full Story

  • 05.20.2022  |  The Battle Against Bugs

    BOSTON BUSINESS JOURNAL | As the threat posed by drug-resistant bacteria continues to grow, the companies striving to develop antibiotics remain notoriously underfunded.

    Full Story

  • 05.19.2022  |  Battle Against Antibiotic-Resistant Bacteria Gets HHS Cash Boost

    BLOOMBERG LAW | The Department of Health and Human Services will commit $20 million this year and has options to provide up to $300 million over the next 10 years to combat antimicrobial resistant (AMR) infections, according to the agency Thursday.

    Full Story

  • 05.19.2022  |  HHS, Wellcome Commit $370M in New Funding for CARB-X

    360DX | CARB-X will receive up to an additional $370 million from the US Department of Health and Human Services and charitable foundation Wellcome to continue funding drug-resistant bacteria research, including the development of diagnostics.

    Full Story

  • 05.19.2022  |  CARB-X receives new round of funding from BARDA, Wellcome

    CIDRAP | The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) today announced renewed funding from the US government’s Biomedical Advanced Research and Development Authority (BARDA) and UK charitable foundation Wellcome.

    Full Story

  • 05.19.2022  |  Antibiotic resistance efforts get a boost as CARB-X gets $370M

    BOSTON BUSINESS JOURNAL | Kevin Outterson has spent the better part of the last year in conversations with CARB-X’s previous backers. Now, those efforts have yielded fruit: The organization has another $370 million to invest in research targeting drug-resistant bacteria.

    Full Story

  • 05.19.2022  |  Can We Prevent Antibiotic Resistance?

    THE BRINK | Antibiotics are losing effectiveness—and millions are dying as a result. CARB-X, a BU-based partnership that aims to solve antimicrobial resistance, has been given up to $370 million in new funding from the US government and charitable foundation Wellcome

    Full Story

  • 05.19.2022  |  HHS commits $300M to global accelerator targeting antibiotic-resistant bacteria

    FIERCE | The Department of Health and Human Services announced Thursday morning a $300 million commitment to supporting a public-private antibiotic-resistant bacteria accelerator over the next decade.

    Full Story

  • 05.12.2022  |  Are Antibiotics Doomed? David Hyun & Erin Duffy on the Crisis No One Talks About

    FREE FORUM PODCAST | In 2019, about 1.27M people died directly due to antimicrobial resistance – significantly more than from Covid in two years. When we lose antibiotics, we will be in a different world. Joint and organ replacement, cancer treatments and many other medical procedures will be a thing of the past. Terrence McNally talks about the growing dangers of antibiotic resistance and the lack of new drugs with David Hyun, MD, who directs the Antibiotic Resistance Project at the Pew Charitable Trust, and Erin Duffy, Chief of R&D at CARB-X.

    Full Story

  • 05.11.2022  |  The antimicrobial pipeline is ‘dry’ and that’s a problem

    PHARMAPHORUM | Antimicrobial resistance is a growing problem and one that is already claiming over a million lives per year. The situation is urgent but finding a sustainable solution is a difficult prospect.

    Full Story

  • 04.27.2022  |  ENTASIS THERAPEUTICS HOLDINGS INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations

    MARKET SCREENER | The report includes a discussion and analysis of Entasis’ financial condition and results of operations.

    Full Story

  • 04.25.2022  |  UK takes subscription approach for new antibiotics

    CHEMISTRY WORLD | The UK has adopted the world’s first subscription payment model for two new antibiotics. The National Health Service will pay Pfizer and Shionogi up to £10 million a year for ten years for them, regardless of how many doses are administered to patients.

    Full Story

  • 04.20.2022  |  SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001

    BENZIGA | SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, announced dosing of the first human subjects in its phase 1 clinical trial with SNIPR001, an orally administered CRISPR-based therapeutic.

    Full Story

  • 04.20.2022  |  Clinical update: SNIPR BIOME doses first human subjects with CRISPR-based antibiotic

    CRISPR MEDICINE NEWS | SNIPR BIOME announced this morning that it has dosed the first participants in a clinical trial for SNIPR0001, an orally administered CRISPR-based therapeutic designed to reduce E. coli colonization in the gut to prevent blood infections in patients with cancer.

    Full Story

  • 04.18.2022  |  An episode about CARB-X with Erin Duffy and Kevin Outterson

    PROGRESS, POTENTIAL & POSSIBILITIES PODCAST | Host Ira Pastor speaks with Erin Duffy and Kevin Outterson about how and why CARB-X supports innovative antibiotics vaccines and diagnostics to treat, prevent and diagnose AMR bacterial infections for a global population.

    Full Story

  • 04.13.2022  |  Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results

    BAKERSFIELD | Vedanta Biosciences, a leading clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced the publication in the journal Cell Host & Microbe of the results from a Phase 1a/1b study evaluating the safety, tolerability, and colonization dynamics of VE303 in healthy adults. VE303 is a potential first-in-class defined bacterial consortium candidate for the prevention of recurrent Clostridium difficile infection (CDI). The company will also share three research updates across its VE303 and VE202 (for inflammatory bowel disease) programs in podium presentations at Digestive Disease Week in May 2022.

    Full Story

  • 04.11.2022  |  Day Zero Diagnostics Announces the Launch of Day Zero Lab Services

    CISION PRWEB | Day Zero Diagnostics, Inc., an infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, today announced the launch of Day Zero Lab Services focused on providing hospitals with services focused on whole-genome sequencing-based assays.

    Full Story

  • 04.07.2022  |  Lumen Bioscience: Spirulina-based platform enables rapid, low-cost development of oral biologics

    BIOPHARMA-REPORTER | Researchers at Lumen Bioscience report in Nature Biotechnology genetic engineering methods to highly express bioactive proteins in spirulina using large-scale cultivation and processing methods appropriate for biopharmaceutical manufacturing.

    Full Story

  • 04.05.2022  |  Boston University Led CARB-X Grants Clarametyx Biosciences an Additional $3.89 Million in Funding to Accelerate Anti-Biofilm Therapy for Bacterial Infections TrialSite Staff April 5, 2022

    TrialSite News | Clarametyx Biosciences, a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilm, announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), has awarded the company an additional $3.89 million in option funding. The grant will be used toward advancing the development of CMTX-101, a novel anti-biofilm therapy with a first targeted indication for moderate-to-severe pneumonia.

    Full Story

  • 04.04.2022  |  Pharma’s ambitious new antibiotic venture fund makes its first investments

    STAT | The AMR Action Fund is providing an undisclosed portion of its $1 billion in initial backing — much of which comes from several of the world’s largest drug manufacturers — toward Venatorx Pharmaceuticals and Adaptive Phage Therapeutics. The two privately held companies are taking a different approach toward developing therapies that can fight drug-resistant infections.

    Full Story

  • 04.04.2022  |  Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund

    HERALD CHRONICLE | Venatorx Pharmaceuticals, Inc., a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, today announced that it sold shares of its Series C Preferred Stock in a financing led by the AMR Action Fund with participation from existing investors including Abingworth.

    Full Story

  • 03.24.2022  |  Integrated Biotherapeutics Awarded $3.55M Grant to Study Immune Correlates of Protection Against Recurrent Staphylococcal Infection

    WFMZ | Study is expected to provide insights into mechanisms of protection against staph infection. IBT and its subsidiary Integrated BioTherapeutic Vaccines (IBV) are developing IBT-V02, a novel vaccine for S. aureus infections with support from CARB-X and Novo Holdings. IBT-V02 will enter Phase 1 clinical trial this year.

    Full Story

  • 03.21.2022  |  Superfood spirulina harnessed as biomanufacturing engine

    HEALTH TECH WORLD | A common food source has been converted into a biomanufacturing platform that enables mass production of biologic drugs for common diseases that currently lack effective treatments. Researchers at Lumen Bioscience have pioneered genetic engineering methods to highly express bioactive proteins in spirulina using large-scale cultivation and processing methods appropriate for biopharmaceutical manufacturing.

    Full Story

  • 03.03.2022  |  Spexis achieves first CARB-X milestone for its thanatin derivatives program and receives funding of up to USD 1.9 million to initiate lead optimization

    BIOSPACE | Spexis has received this award based upon the achievement of technical milestones within the previously announced CARB-X collaboration for this program. The award will support the continuation of the "thanatin derivatives program" belonging to Spexis' novel Outer Membrane Protein Targeting Antibiotic (OMPTA) class of antibiotics to potentially treat life-threatening infections caused by difficult-to-treat Gram-negative bacteria.

    Full Story

  • 03.02.2022  |  Combating AMR with Diagnostics

    BIOSPECTRUM | Early diagnosis plays a significant role in effective management of AMR. Faster and accurate diagnostic tests enable identification and pathogen identification so patients can be treated with the most appropriate drug quickly. This prevents antibiotic misuse and overuse, and can play a vital role in timely interventions to improve patient outcomes and reduce the spread of resistance.

    Full Story

  • 02.28.2022  |  The Global Burden of AMR

    INFECTIOUS CONVERSATIONS PODCAST | Episode 1 features Kevin Outterson (CARB-X), Dr. Helen Boucher (Tufts University School of Medicine), and Mary Booth Dwight (Cystic Fibrosis Foundation) who discuss the global burden of AMR.

    Full Story

  • 02.17.2022  |  Report highlights ‘fragile and failing’ antibiotic pipeline

    CIDRAP | The report on antibacterial innovation from the Biotechnology Innovation Organization (BIO) concludes that the breadth and the novelty of the clinical antibacterial pipeline is insufficient to meet the growing threat of antibiotic-resistant pathogens.

    Full Story

  • 02.16.2022  |  The hidden epidemic

    VOX | Antibiotic resistance is approaching a crisis point, and the world needs to act

    Full Story

  • 02.05.2022  |  Antibiotic Resistant Bacteria, A Growing Global Threat

    HealthCall LIVE | Lee Kelso talks with Kevin Outterson from CARB-X about the risk of bacteria that antibiotics can’t kill and the search for effective drugs.

    Full Story

  • 02.01.2022  |  AMR Action Fund Appoints Scientific Advisory Board

    AMR ACTION FUND | Members will play a vital role in evaluating potential investments into clinical-stage companies developing urgently needed antibiotics

    Full Story

  • 01.27.2022  |  The World’s Next Big Health Emergency Is Already Here

    BLOOMBERG OPINION | Covid-19 has claimed nearly 6 million lives. Antimicrobial resistance may claim 10 million annually by 2050 — and that figure is starting to look low.

    Full Story

  • 01.27.2022  |  AMR Action Fund head aims to boost innovation, funds for new antibiotics

    CIDRAP | The science is not the issue, experts say. The big problem is the lack of a viable market for new antibiotics, one that reimburses antibiotic developers for the public health value of their product.

    Full Story

  • 01.27.2022  |  RTP’s Locus Biosciences grows as it tackles issue of drug-resistant bacteria

    THE NEWS & OBSERVER | Locus Biosciences is expecting more growth in 2022, as the gene-editing company strives to provide alternatives to the pressing issue of drug-resistant bacteria.

    Full Story

  • 01.26.2022  |  Drug-Resistant Superbugs Are Causing More Deaths: What’s Being Done?

    HEALTHLINE | For years, scientists have been sounding the alarm about how so-called superbugs can be life threatening. Now, a new study outlines just how life threatening that drug resistance is when it comes to antibiotics, or what scientists call antimicrobial resistance.

    Full Story

  • 01.24.2022  |  AMR May Be the ‘Next Pandemic’

    MEDPAGE TODAY | Feds lead investment in antimicrobial resistance, but more private help is needed, BARDA says

    Full Story